top of page
Endometrial Cancer


A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2
A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-Iv Endometrial Serous Carcinoma Or Carcinosarcoma (NRG-GY026)

GynOnco Group Team
Aug 16


Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005/TroFuse-005/GOG-3095)
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005/TroFuse-005/GOG-3095)

GynOnco Group Team
Aug 15


A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Can
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Can

GynOnco Group Team
Aug 15

CONTÁCTANOS
DIRECCIÓN
TORRE MÉDICA AUXILIO MUTUO
PISO 8 SUITE 812
#735 AVE. PONCE DE LEÓN
SAN JUAN, PUERTO RICO

TELÉFONO
HORARIO
Lunes - Viernes
8:00 am – 4:00 pm
bottom of page